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Fabry disease (FD), caused by deficiency of the lysosomal enzyme α-galactosidase-A, is a progressive multisystem
disease. The disease is X-linked with generally more severe manifestations in males, but can impact on quality of life
(QoL) of both male and female patients. The purpose of this literature review is to analyse the currently available data
concerning QoL measurement, specifically which questionnaires have been used to measure QoL, how patients with
FD score compared to the general population, and the effects of enzyme replacement therapy (ERT) on QoL. Fifty-four
articles were relevant for this literature review. Patients with FD had a lower QoL compared to the general population.
No definite conclusions could be drawn from the studies on the effect of ERT on QoL; natural history data is scarce,
changes observed were limited and the cohorts were of small size. We propose that a FD specific questionnaire be
made to accurately assess QoL in patients with FD.
Keywords: Fabry disease, Quality of life, Health related quality of life, Patient reported outcome measures, Enzyme
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Fabry disease (FD) (OMIM#301500) is a rare X-linked
lysosomal storage disorder. The disease is characterized
by deficiency of the lysosomal enzyme α-galactosidase A
(α-Gal A, E.C. 3.2.1.22). This results in a systemic accu-
mulation of globotriaosylceramide (Gb3) and related gly-
cosphingolipids in lysosomes in cells throughout the
body. The prevalence of FD is estimated at 1:40.000–
170.000 live births [1–3] although recent newborn and
high-risk group screening studies suggested that the
prevalence of non-classical FD may be much higher than
previously thought [4, 5]. Phenotypically, FD can be
distinguished in the more severe classical form of FD,
predominantly affecting males, and a non-classical form,
more prominent in males with residual enzyme activity.
Although females can be as severely affected as male
patients with classical FD, most of them have a more
variable and attenuated phenotype and are therefore bet-
ter characterised as non-classical patients [6].
Early symptoms in classically affected male and female
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creativecommons.org/publicdomain/zero/1.0/pain, gastrointestinal symptoms and microalbuminuria.
Later in life, progressive renal failure, heart failure and
stroke generally occur. In non-classically affected male
patients and most females, the disease presents with a
more attenuated and variable disease course [7–11]. The
shortened life expectancy and the morbidity of Fabry pa-
tients are strongly related to the degree of end-organ
damage.
Currently, two enzyme preparations are available for
the treatment of FD (agalsidase alfa, Shire HGT, Boston
MA, USA, and agalsidase beta, Genzyme Inc, Boston
MA, USA). The initial clinical trials showed beneficial
effects on neuropathic pain, cardiac mass and kidney
function. However, it has been shown that despite en-
zyme replacement therapy (ERT), disease complications
may still occur [12–14].
Patients who suffer from FD have a lower quality of
life (QoL) compared to healthy individuals. Neuropathic
pain and anhidrosis are predictors of decreased QoL,
presumably as a marker of more severe disease [3]. It
has been postulated that ERT has a positive effect on
QoL [15, 16]. However, these studies used different mea-
sures of QoL and were only reported for small cohorts
of patients. Interest in QoL measurements has increased
over the past decades, because it is well recognized that,rticle distributed under the terms of the Creative Commons Attribution License
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psychological factors play an important role in the lives
of patients with FD. Additionally, patient involvement
with decision making and assessment of quality of care
is increasing. Lastly, QoL measurements are needed for
cost-effectiveness analyses, nowadays a requirement for
reimbursement of therapy for some governments in the
EU [17]. It is therefore important to gain a good under-
standing of the information available to us now.
This systematic review provides an overview of the
current literature with the aim to improve our under-
standing of the QoL amongst patients with FD and to
enhance the appropriate use of QoL instruments in clin-
ical practice. We specifically focus on which QoL mea-
sures have been used to determine if these different
measures reveal similar results. Furthermore we review
the literature on the potential effect of ERT on QoL.
Methods
Search strategy and study selection
The following electronic databases have been searched
via OvidSP: Medline (1946 till December 10, 2014),
Embase (1947 till December 10, 2014) and PsycInfo
(1806 till December week 1, 2014). The Cochrane Cen-
tral Register of Controlled Trials (CENTRAL, accessed
December 10, 2014) has been searched as well.
The search terms used were: Fabry disease, quality of
life, questionnaires, SF-36, EQ5D, pain measurement, BPI,
peds QL, and their synonyms, Mesh terms (Medline) and
headings (Embase). No limits were used. Detailed search
strategies can be found in Additional file 1.
The title and abstract of all articles obtained by the
search were screened to identify studies where quality of
life in patients with FD was studied. Reference lists of
identified papers were hand searched for additional rele-
vant citations. Original articles published in English,
French and German were included. Case reports, case
series on less than 5 patients, and review articles were
excluded.
Data extraction
Data were recorded on the type of study (clinical trial,
cohort study, before-after study, case series or registry
study), number of subjects, gender and age groups
(children and/or adults), together with the type of ques-
tionnaire used to assess QoL, disease severity and ther-
apy status at the time of QoL assessment.
Statistical analyses
A meta-analysis was performed on studies reporting SF-
36 or RAND-36 results using a fixed effect inverse
variance weighting. Meta-analysis of other QoL mea-
surements was not feasible because data were either not
given in sufficient detail or QoL instruments were onlyused in single studies. Articles were included in the
meta-analysis when mean domain scores with standard
deviations or confidence intervals were provided. Pooled
analysis for all studies combined, as well as for sub-
groups of studies, were performed. Subgroups were de-
fined as: (1) studies performed in the period before ERT
was available (untreated, mostly classically affected
patients), (2) studies on the effect of ERT that report
baseline measurements (untreated patients but with a
treatment indication) and (3) studies in which only ERT
treated patients were included. Results from the Bodily
Pain and General Health subdomains from the RAND-
36 were excluded because different scoring algorithm
are used for these subdomains.
Results
The electronic search resulted in 532 publications.
Cross-checking reference lists revealed four additional
relevant papers. After removal of duplications 368 arti-
cles remained. One hundred eighty seven articles were
selected based on title and abstract. A total of 54 articles
were eligible for inclusion in this review (see Additional
file 2) of which 26 reported detailed QoL data. A flow
diagram is presented in Fig. 1.
Questionnaires used to assess QoL in FD
Fifteen different questionnaires have been used to assess
QoL in FD populations, amongst which the Short Form
(36) Health Survey (SF-36), the EuroQoL five dimen-
sions questionnaire (EQ-5D) and the interference score
of the Brief Pain Inventory (BPI) were the most fre-
quently used measures. A short description of these
questionnaires is given below.
Other questionnaires used were: the Anderson-Fabry
Disease specific questionnaire [7, 18, 19], Child Health
Questionnaire [20], Fabry-Specific Pediatric Health and
Pain Questionnaire (FPHQP) [21], KINDL [21], PedsQL
[22], RAND-36 [23], Rankin scale [24], WHOQOL-100
[25] and four locally developed questionnaires [26–29].
SF-36 and RAND-36
The SF-36 [30] questionnaire assesses 8 domains of
QoL: (1) Physical Functioning, (2) Role Physical, (3)
Bodily Pain, and (4) General Health, (5) Vitality/Energy,
(6) Social Functioning, (7) Role Emotional, and (8) Men-
tal Health. SF-36 domain scores range from 0 to 100.
The 8 domains can be grouped into two summary
scores: the Physical Component Summary (PCS) and the
Mental Component Summary (MCS). These scores are
computed by multiplying each of the 8 individual SF-36
scores by their specific factor score coefficients. MCS
and PCS are norm based summary scores, which are
standardised with a T-score transformation resulting in a
mean of 50 with a standard deviation of 10. Studies of
Fig. 1 Flow chart of identification, screening and inclusion of articles in the systematic review
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tient groups have suggested a 3 to 5 point change on
any SF-36 scale as minimally clinically important differ-
ence (MCID) [31]. The RAND-36 [32] is virtually identi-
cal to the SF-36 however for the domains General
Health and Bodily pain the scoring algorithms are
different.EQ-5D and EQ-VAS
The EQ-5D questionnaire is comprised of 5 domains:
(1) mobility, (2) self-care, (3) anxiety/depression, (4)
usual activities and (5) pain/discomfort [33]. Each do-
main has 3 levels of severity: (1) no problems, (2) some
or moderate problems, and (3) extreme problems.
Results from the EQ-5D descriptive system can be con-
verted into a utility score for the calculation of quality-
adjusted life years (QALYs) via an algorithm that uses
population-based preferences. Utility scores range from
−0.11 (all five ED-5D health domains reported extreme
problems) to 1 or perfect health (no problems at all five
EQ-5D domains), in which zero means dead and nega-
tive utility scores represent health states worse than
dead. A difference or improvement of 0.074 is consid-
ered to be of clinical importance [34]. The EuroQol
Visual Analog Scale (EQ-VAS) is a visual analogue scaleranging from 0 to 100 which assesses health state. The
minimal important difference is considered to be 7 [35].
BPI
The Brief Pain Inventory (BPI) [36] has been designed to
assess the severity of pain and the impact of pain on
daily functions. The latter is reflected by the BPI inter-
ference score, which is the average of the following
interference subscales: general activity, mood, walking
ability, normal work, relations with other people, sleep
and enjoyment of life. These subscales are scored from 0
to 10, with an estimated minimal important difference of
1 or 0.5 SD [37].
QoL in patients with FD versus the general population
Eleven studies that investigated QoL in a cohort of FD
patients with the SF-36 or the RAND-36 supplied suffi-
cient data for the meta-analysis [3, 16, 19, 23, 38–44].
The results of this meta-analysis (males and females, and
treated and untreated patients combined) are depicted
in Fig. 2. In general, patients with FD scored worse
across all domains compared to the general population
[45]. Seven studies reported sufficient data to stratify re-
sults by gender and ERT treatment status [3, 16, 19, 38,
41, 42, 44]. Pooled SF-36 scores of these 7 studies are
presented in Fig. 3.
Fig. 2 Pooled results of SF-36 subdomain scores. Weighted mean
and SEM. Results from treated and untreated, male and female
patients. Reference population derived from Jenkinson et al. [45]. PF
Physical Functioning, RP Role Physical, BP Bodily Pain, GH General
Health, VT Vitality, SF Social Functioning, RE Role Emotional, MH
Mental Health
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43, 46]. Pooled analysis (males and females, and treated
and untreated patients combined) revealed a weighted
mean of the PCS and MCS of 42.8 (SEM: 0.62) and 48.7
(SEM: 0.52), respectively.
The studies that only mentioned whether or not QoL
was better or worse compared to the general population,
without providing exact scores, supported these findings;Fig. 3 Pooled results of SF-36 subdomain scores stratified by gender and t
role physical, BP bodily pain, GH general health, VT vitality, SF social functiothey all showed that QoL in Fabry patients was worse
for some or all domains [47–52].
In total, 7 studies used the EQ-5D to compare QoL in
patients with FD versus the general population. In 2 stud-
ies mean EQ-5D utility scores of 0.66 [53] and 0.56 [19]
were reported. The first study was performed in a mixed
cohort consisting of males and females, either treated or
untreated, while the latter comes from the pre-ERT era
and studied only male patients. These scores were both
significantly lower than the general population, with 1 of
these 2 studies reporting an estimated difference of −0.23
[53]. The third study reported a mean difference of −0.24
in a combined cohort of treated and untreated male and
female patients compared with the general population,
also a significant difference [54]. Two other studies only
mentioned that the EQ-5D score was lower, in a cohort of
primarily treated male patients and a cohort of treated fe-
male patients without providing any exact data [51, 55].
Finally, two studies reported EQ-VAS scores in mixed co-
horts of 21 [40] and 33 [44] untreated and treated FD pa-
tients which were significantly lower compared to the
general population and matched controls, respectively.
One study used the BPI interference score to measure
pain related QoL in male and female patients with FD,
either treated or untreated. Compared to age- and gen-
der matched healthy controls, they scored significantly
worse (0.4 versus 2.0) [46].
In addition, several other studies suggested a negative
influence of FD on QoL, but no comparison with a ref-
erence population was made [7, 8, 18, 28, 29, 56, 57].
The relation between QoL, disease severity and age
Renal disease, disease severity and age are related to
QoL in FD. Renal disease impacts on the QoL of FDreatment status. Weighted mean and SEM. PF physical functioning, RP
ning, RE role emotional, MH mental health
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scores except for Mental Health were reported among
FD patients with an eGFR of >60 ml/min/1,73 m2, pa-
tients with an eGFR of <60 ml/min/1,73 m2 and patients
receiving renal replacement therapy (RRT). Median PCS
scores were 49.8 (eGFR >60), 35.9 (eGFR <60) and 29.4
(RRT). The MCS scores were 47.1 (eGFR >60), 49.8
(eGFR <60) and 30.1 (RRT) [58]. Others have shown a
negative correlation between MSSI (Mainz Severity
Score Index) scores and QoL [39, 55], which was sup-
ported by Rombach et al. who defined four disease
states; asymptomatic, acroparasthesia/symptomatic, sin-
gle complication and multiple complications, and found
lower EQ-5D utility scores with more severe disease
(0.87, 0.76, 0.74, and 0.58 per state, respectively) [59].
Hoffmann et al. investigated specifically gastro-intestinal
(GI) complaints amongst male and female patients with
FD and unknown treatment status [60]. Using the EQ-
5D, patients with GI complaints had a lower EQ-5D
score than those without GI complaints.
In line with the relation between disease severity and
QoL, higher age has been associated with lower QoL [9,
19, 22, 39]. Qol in males starts to decline at younger age
than in female patients as shown by a Fabry Registry (a
Genzyme sponsored post-marketing drug registry) study
in which males between 18 and 25 years of age had sig-
nificantly lower SF-36 scores in 6 of 8 subdomains whilst
females had normal scores in all but the subscales Bodily
Pain and General Health [9]. Above the age of 25, both
males and females showed impaired QoL in the subdo-
mains Physical Functioning, Bodily Pain, General Health
and Vitality. Females scored better in the Social Func-
tioning domain, while males scored better in the Mental
Health subscale [9].
Effect of ERT on QoL
Two studies reported detailed SF-36 scores to show the
effect of ERT on QoL. One Phase IIIB study in 15 female
patients with clinical evidence of FD (i.e. involvement of
at least 3 organ systems) reported baseline scores [38].
In addition, scores were reported after 13 and 27 weeks
of treatment. No control group was included. After
13 weeks of treatment no changes were seen. At week
27, domain scores for Role Physical and General Health
were increased, while the other domain scores stayed
stable. PCS was 35 (SD: ±12) at baseline, stayed stable
after 13 weeks and improved by 6.6 (SD: ± 6.0) after
27 weeks of treatment. MCS was 40 (SD: ±15) at base-
line, and similar scores were found after 13 and 27 weeks
of treatment.
The second study, based on data from the Fabry Regis-
try, investigated the mean change after 24 months of
treatment compared to baseline for males and females
separately [16]. Although the Fabry Registry had data of3128 patients at that time, only for 71 male patients
baseline QoL data and three post treatment assessments
during a period of 36 months were available. In addition,
59 female patients had baseline and at least 2 post treat-
ment assessments during a period of 24 months. Limited
data on genotype, phenotype and disease severity were
given. Males showed improvements for all 8 domains
after 24 months of treatment with changes from baseline
ranging between 4.6 in the Mental Health domain to
14.6 in the Role Physical domain. Females also showed
improvements from baseline after 24 months of treat-
ment for Bodily Pain, Vitality, Social Function and
Mental Health; 6.1, 7.3, 8.4 and 5.1 respectively. Other
domain scores did not change significantly. PCS and MCS
scores were calculated at baseline, 12 months and
24 months in the male and female groups, and after
36 months in the male group only. Male PCS and MCS
scores were 39 (SD: ±10.9) and 46 (SD: ±10.3) at baseline
and did not change significantly after 36 months. Likewise,
female PCS scores (baseline score: 37 (SD: ±12.9))
remained stable. MCS scores of females improved from 46
(SD: ±11.8) to 49 (SD: ±11.5) after 24 months.
One study measured mean scores for all domains at
baseline, 4 years and 7 years of treatment [61]. Mean SF-
36 domain score was 62 (SD: ±19) at baseline and 59
(SD: ±21) after 4 years. After 7 years of treatment the
mean score was 57 (SD: ±16) coming from 66 (SD: ±18)
at baseline. Changes were not statistically significant,
except for the subdomain Social Functioning which
worsened significantly after 7 years of therapy. This
abstract did not provide patient characteristics, study
type, nor detailed baseline and follow-up scores.
Seven studies did not report mean SF-36 domain or
summary scores but only mentioned if improvements
were observed [48, 51, 62–66]. Five studies mentioned
improvements in one or more domains after introduc-
tion of ERT, while two studies reported no significant
change after 24–36 months of treatment [51, 66]. One of
these studies included a placebo group [62]. Both the pa-
tients in the placebo and the treatment group showed
improvements in the domain Role Physical. In addition,
treated patients showed improvement in Role Emotional
whereas the placebo patients showed an improvement in
the domain Bodily Pain. A study that assessed the rela-
tion between treatment duration and QoL reported a
negative correlation between time on ERT and SF-36
PCS and MCS scores [22].
Three studies, all using Fabry Outcome Survey (FOS, a
Shire sponsored post-marketing drug registry) data, used
the EQ-5D to measure the effect of ERT on QoL [53, 54,
67]. Baseline scores were between 0.61 and 0.64, and im-
provements to 0.74 after 1 year of treatment, and a trend
towards improvement to 0.69 in males and 0.72 in
females after 4 years of treatment was observed [53, 67].
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the general population [54]. At the start of treatment the
score was −0.24 lower than the general population and
after 5 years of treatment −0.17 below the general popu-
lation. Wyatt et al. studied the relation between time on
ERT and EQ-5D score and found no significant correl-
ation, while EQ-VAS reduced with increased treatment
duration [22] A randomised controlled trial in 14 male
patients on the efficacy of agalsidase alfa showed a sig-
nificant difference in change from baseline in BPI inter-
ference scores after 24 weeks of ERT, favouring the ERT
treatment group (−1,1 vs −0.6) [15]. A second random-
ized controlled trial did not find an effect of different
dosing regimens on this score in the short term [68].
Two studies reported on the effect of home based in-
fusion therapy in comparison to hospital based infusion
therapy. A before-after study showed improvement of all
SF-36 subscales except Physical Functioning [69]. A
cross-sectional study reported less stress and less nega-
tive impact on family life after introduction of home
treatment [27].
Effect of the shortage on QoL
In 2009 a temporary worldwide interruption of enzyme
supply led to dose reductions or cessation of treatment
in groups of FD patients [70]. Three studies investigated
the effect of dose decrease or interruption on QoL. Two
articles used the SF-36 questionnaire and one article
used EQ-5D. The first study using combined data from
patients on lower doses of agalsidase beta and patients
who switched to agalsidase alfa, showed lower scores for
females in the General Health and Vitality domains dur-
ing the shortage [42]. The second reported no change in
MCS and PCS scores after dose reduction of agalsidase
beta [71]. The latter, using EQ-5D, showed no change
after the switch from agalsidase beta to agalsidase alfa,
although a trend towards improvement was seen [72].
QoL in children with FD
In a paediatric cohort of 87 children (boys and girls com-
bined) the mean EQ-5D utility score was 1.00 (SD ±0.0),
the mean of the interference score of the BPI was 0.76
(SD 1.47), and the KINDL showed a moderate impact on
QoL and daily life, with the most severely affected do-
mains being personal feeling, family and friends [21]. In
22 boys and girls of whom seven received ERT the total
PedsQL score as well as the subscales physical functioning
and school functioning decreased with age, while no rela-
tion with time on ERT was found [22]. BPI interference
scores decreased after introduction of ERT in 13 children
[73]. In nine children (age <10) all subscales of the Child
Health Scores were lower, but only bodily pain and mental
health were significantly different from a healthy control
population. Children above the age of 10 years only scoredworse on the bodily pain domain compared to the control
population [20]. Thirty-six adolescent patients scored
worse on the SF-36 compared to general population; boys
reported decreased QoL in all subscales, except for Role
Emotional, while females scored worse in the subscales
Bodily Pain and General Health [74].QoL in FD vs other chronic illnesses
Street et al. investigated data from female FD patients
and compared them with cohorts with multiple sclerosis
(MS) and rheumatoid arthritis (RA) using the RAND-36
[23]. Females with FD scored better on the Physical
Functioning domain than MS and RA patients (67 ver-
sus 37 and 51, respectively). Similar scores were found
in patients with FD and patients with MS in the domains
Role Emotional, Energy and Emotional Well-being pa-
tients with FD while RA patients scored better. Social
functioning and Role Physical scores in patients with FD
were comparable to those in patients with RA, while pa-
tients with MS scored worse in these domains. Pain
scores of FD patients were worse than those in MS pa-
tients but better than those in RA patients (62 versus 74
and 56, respectively). General health is lower in patients
with FD than in patients with MS and RA (45 versus 53
and 51, respectively). A second study compared patients
with FD to patients with RA, MS, central neuropathic
pain and Gaucher disease (GD). Baseline SF-36 scores
were similar to MS and GD patients. General Health
and Vitality scores in patients with FD were comparable
to those in RA and central neuropathic pain patients
[16]. A third study reported substantially lower General
Health, Vitality, Social Functioning, Role Emotional and
Mental Health domain scores in female patients with FD
compared to patients with RA [38].
In addition, patients with FD have been compared to
severe hemophiliacs [19]. MCS and EQ-VAS scores were
lower in patients with FD; PCS scores and EQ-5D were
similar in both populations. Finally, a study using
WHOQoL-100 compared QoL of FD patients with that
of PKU patients [25]. General QoL as well as the phys-
ical, independence, facet medication domains were lower
in patients with FD. The scores in the psychological,
spiritual and environmental domains were similar.Discussion
This systematic review of quality of life in Fabry patients
from 54 articles and abstracts has led to two major find-
ings. Firstly, a consistent finding from all studies is that
Fabry patients suffer from a considerably worse quality
of life as compared with the general population. This
was found for all domains in the SF-36 and in the EQ-
5D questionnaires. Secondly, the studies on the effect of
ERT on QoL are inconclusive.
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FD clearly have lower QoL scores in comparison with
the healthy population. However, in the interpretation of
these results, some of the study characteristics need to
be taken into consideration; firstly, disease severity is
rarely comprehensively reported and if reported, the data
varies between studies. Rombach et al. showed that
disease severity plays an important role for measuring
QoL and should therefore be taken into account when
measuring QoL scores [59]. This is further supported by
the finding of a correlation between the MSSI (a meas-
ure for disease severity) and QoL [39, 55]. In addition,
more severe kidney disease has been shown to lead to
reduced QoL, in particular after initiation of renal re-
placement therapy. [58]. Also, no studies on the differ-
ence in QoL between patients with either classical or
non-classical FD have been performed, although this
would have been interesting considering their different
disease courses. The influence of phenotype is illustrated
by Gold et al., who measured SF-36 scores for untreated
male patients before the introduction of ERT. In these
severely, mostly classically affected males, domain scores
ranged between 24 and 61, which is worse compared to
QoL scores found after the introduction of ERT, even if
only baseline scores (prior to start of ERT) are consid-
ered. This difference can be partly explained by the in-
clusion of non-classical patients in the more recent
studies. In addition, most studies investigated a Fabry
population consisting of both males and females. As
noted by Wilcox et al. differences are observed between
males and females and at what age the quality of life
starts to decline for either gender [9]. Both are factors
that need to be taken into consideration. Thirdly, many
of the cohorts studied consisted of treated and untreated
patients together. More studies in subgroups of patients
are needed to gain a better insight into the influence of
phenotype, gender and treatment on QoL.
If specifically looking at the effect of ERT on QoL,
only a limited number of studies reported baseline and
follow-up data in detail, showing different results. One
study of only women, with a small sample size and with-
out a control arm discovered a very minor change after
27 weeks. Another study reported a minimal improve-
ment in BPI interference score after 24 weeks, although
it should be noted that baseline BPI scores were differ-
ent between both treatment arms and decreased in both
groups [15]. One might argue that 6 months is too short
to detect any effect from ERT on QoL scores. However,
a third study showed no change in subdomains of the
SF-36 after 4 and 7 years of therapy except for Social
Functioning, which worsened after 7 years of therapy
[61]. Another explanation could be that the question-
naires are not sensitive enough to show a clear effect in
patients with FD. Baumstarck et al. demonstrated thatgeneric questionnaires often are more suitable for uni-
versal applications where QoL is compared in different
populations, while disease specific instruments focus on
particular health problems and are more sensitive for de-
tecting and quantifying small changes [75, 76]. This
would suggest that a Fabry specific QoL questionnaire
would provide a more sensitive tool to investigate the ef-
fects of ERT on the QoL. At this point no validated FD
specific QoL questionnaire exists and it would be worth-
while to develop such a questionnaire for this patient
group. The studies based on data from the Fabry Regis-
try or Fabry Outcome Survey all showed an improve-
ment [16, 53, 54, 67]. Despite being large, these
registries have their shortcomings as has been published
by Hollak et al. [77]. Follow-up data on QoL of only a
very small percentage of patients enrolled in these regis-
tries were available for the analysis making the results
susceptible to selection bias. Furthermore, the limited
information on genotype, phenotype and disease severity
of the patients in these registry studies makes compari-
son between cohorts impossible. Finally, differences
before and after therapy are small, especially when com-
paring to the 3–5 point (SF-36) or 0.074 (EQ-5D) min-
imally clinically important difference (MCID). However,
whether the standard MCID’s are applicable to FD can
be questioned. For example, Wyrwich et al. demon-
strated that three different expert panels provided three
different Clinically Important Differences for three dif-
ferent diseases; chronic obstructive pulmonary disease
(COPD), asthma, and heart disease, respectively [78].
This would imply that a FD specific MCID needs to be
defined for an optimal interpretation of the results.
Altogether, no clear answer can be given whether ERT
has a positive or negative effect on standard QoL scores
in patients with FD.
Apart from the need for more sensitive questionnaires
and disease specific MCID’s, another important caveat is
the lack of QoL data from untreated patients with similar
disease severity as those treated with ERT. Only two
short-term placebo-controlled trials of ERT in FD with
QoL as a secondary outcome measure have been per-
formed. One of those studies revealed significant improve-
ment in both placebo and treated arms [62], while the
other showed a small improvement in BPI interference
score compared to the placebo group [15]. The 3 studies
published on the effects of the shortage did provide us
with an opportunity to see how ERT affected the QoL
once the preparation or dose was changed. However, these
studies were of relatively short duration and no clear con-
clusion can be drawn from the results. Two studies re-
ported stable QoL scores, while one study established a
decline in two subdomains of the SF-36, only in female
patients [42]. Whether anxiety of patients due to the situ-
ation of shortage played a role is unknown as well.
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cost effectiveness analyses to aid in reimbursement deci-
sions. SF-36 and EQ-5D utility scores play a central role
in these analyses. Based on these scores, QALY’s are cal-
culated and subsequently used to obtain costs per
QALY. This development stresses the importance for
the collection of high quality QoL data both before and
during treatment.
Conclusion
Patients who suffer from FD have a considerably lower
QoL compared to the general population; this was
shown in two generic questionnaires, the EQ-5D and
the SF-36. The effect of ERT is however inconclusive;
small cohorts, lack of data and limited natural history
data hamper a definite conclusion. We propose that a
FD specific QoL questionnaire is developed to accurately
monitor patients who suffer from this disease.
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